LifeMD Inc. (LFMD)
NASDAQ (NMS) NASDAQ (NMS) Primary 
LifeMD, Inc. (LFMD) Reports Q3 Loss, Lags Revenue Estimates
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.20 per share a year ago.
LifeMD Shares Decline Even After the Launch of Testosterone Therapy
LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.
LifeMD: Selling WorkSimpli Could Be A Catalyst
LifeMD's Q2 2024 earnings were mixed, with management failing to monetize the non-core WorkSimpli asset, leading me to assign it no value. Despite management's over-promising, LifeMD's telehealth and GLP1 offerings show significant potential, with the stock priced at 14x forward EBITDA. I have revised my price target from $20 to $15 per share by summer 2025, due to management's credibility issues and uncertainties in GLP1 prospects.
LifeMD, Inc. (LFMD) Q2 2024 Earnings Call Transcript
LifeMD, Inc. (NASDAQ:LFMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Justin Schreiber – Chairman and Chief Executive Officer Marc Benathen – Chief Financial Officer Conference Call Participants David Larsen – BTIG Steve Dechert – KeyBanc William Wood – B. Riley Securities Sarah James – Cantor Yi Chen – H.C.
LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.23 per share a year ago.
LifeMD: High Growth GLP-1 Telehealth Play At A Discount
LifeMD is positioned as a high-growth telehealth play with a focus on GLP-1 weight management treatments. The company is guiding for 35% revenue growth in 2024. Its core telehealth business is expected to grow at least 43%. Non-core software subsidiary WorkSimpli may be spun off in the next 6 to 12 months, while the company is on track for GAAP profitability next year.
LifeMD Can Surge on Its GLP-1 Offerings
LifeMD Inc. NASDAQ: LFMD is a leading telehealth provider operating an end-to-end virtual healthcare platform. LifeMD operates a direct-to-consumer (DTC) model focused on offering on-demand primary care services to consumers.
